Nanhua Bio Medicine Co Ltd (000504) - Net Assets
Based on the latest financial reports, Nanhua Bio Medicine Co Ltd (000504) has net assets worth CN¥369.07 Million CNY (≈ $54.01 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.02 Billion ≈ $148.73 Million USD) and total liabilities (CN¥647.35 Million ≈ $94.73 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 000504 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥369.07 Million |
| % of Total Assets | 36.31% |
| Annual Growth Rate | 13.48% |
| 5-Year Change | 224.07% |
| 10-Year Change | 348.24% |
| Growth Volatility | 263.26 |
Nanhua Bio Medicine Co Ltd - Net Assets Trend (1989–2025)
This chart illustrates how Nanhua Bio Medicine Co Ltd's net assets have evolved over time, based on quarterly financial data. See 000504 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Nanhua Bio Medicine Co Ltd (1989–2025)
The table below shows the annual net assets of Nanhua Bio Medicine Co Ltd from 1989 to 2025. For live valuation and market cap data, see Nanhua Bio Medicine Co Ltd (000504) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥357.51 Million ≈ $52.31 Million |
+26.78% |
| 2024-12-31 | CN¥282.00 Million ≈ $41.27 Million |
-7.44% |
| 2023-12-31 | CN¥304.67 Million ≈ $44.58 Million |
+281.39% |
| 2022-12-31 | CN¥79.88 Million ≈ $11.69 Million |
-27.59% |
| 2021-12-31 | CN¥110.32 Million ≈ $16.14 Million |
-17.97% |
| 2020-12-31 | CN¥134.48 Million ≈ $19.68 Million |
+17.50% |
| 2019-12-31 | CN¥114.46 Million ≈ $16.75 Million |
+6.22% |
| 2018-12-31 | CN¥107.75 Million ≈ $15.77 Million |
-16.10% |
| 2017-12-31 | CN¥128.43 Million ≈ $18.79 Million |
+61.03% |
| 2016-12-31 | CN¥79.76 Million ≈ $11.67 Million |
+649.85% |
| 2015-12-31 | CN¥-14.51 Million ≈ $-2.12 Million |
-306.42% |
| 2014-12-31 | CN¥7.03 Million ≈ $1.03 Million |
+96.81% |
| 2013-12-31 | CN¥3.57 Million ≈ $522.49K |
+117.16% |
| 2012-12-31 | CN¥-20.80 Million ≈ $-3.04 Million |
-115.96% |
| 2011-12-31 | CN¥130.38 Million ≈ $19.08 Million |
-19.09% |
| 2010-12-31 | CN¥161.13 Million ≈ $23.58 Million |
+11.67% |
| 2009-12-31 | CN¥144.30 Million ≈ $21.12 Million |
-48.12% |
| 2008-12-31 | CN¥278.16 Million ≈ $40.70 Million |
-38.05% |
| 2007-12-31 | CN¥449.00 Million ≈ $65.70 Million |
+1.18% |
| 2006-12-31 | CN¥443.78 Million ≈ $64.94 Million |
-0.47% |
| 2005-12-31 | CN¥445.86 Million ≈ $65.24 Million |
+0.45% |
| 2004-12-31 | CN¥443.86 Million ≈ $64.95 Million |
+4.81% |
| 2003-12-31 | CN¥423.50 Million ≈ $61.97 Million |
+9.35% |
| 2002-12-31 | CN¥387.30 Million ≈ $56.67 Million |
+20.17% |
| 2001-12-31 | CN¥322.29 Million ≈ $47.16 Million |
-16.45% |
| 2000-12-31 | CN¥385.75 Million ≈ $56.45 Million |
+122.30% |
| 1999-12-31 | CN¥173.52 Million ≈ $25.39 Million |
-50.80% |
| 1998-12-31 | CN¥352.69 Million ≈ $51.61 Million |
-36.01% |
| 1997-12-31 | CN¥551.14 Million ≈ $80.65 Million |
+1.86% |
| 1996-12-31 | CN¥541.09 Million ≈ $79.18 Million |
-13.31% |
| 1995-12-31 | CN¥624.18 Million ≈ $91.34 Million |
+3.01% |
| 1994-12-31 | CN¥605.96 Million ≈ $88.67 Million |
+9.46% |
| 1993-12-31 | CN¥553.60 Million ≈ $81.01 Million |
+217.54% |
| 1992-12-31 | CN¥174.34 Million ≈ $25.51 Million |
+57.72% |
| 1991-12-31 | CN¥110.54 Million ≈ $16.17 Million |
+86.52% |
| 1990-12-31 | CN¥59.26 Million ≈ $8.67 Million |
+1471.98% |
| 1989-12-31 | CN¥3.77 Million ≈ $551.67K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nanhua Bio Medicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52211783605.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥787.87 Million | 296.47% |
| Total Equity | CN¥265.75 Million | 100.00% |
Nanhua Bio Medicine Co Ltd Competitors by Market Cap
The table below lists competitors of Nanhua Bio Medicine Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanxi Antai Group Co Ltd
SHG:600408
|
$378.63 Million |
|
Kolon Life Science Inc
KQ:102940
|
$378.83 Million |
|
Matrix Service Co
NASDAQ:MTRX
|
$378.96 Million |
|
Neosem Inc
KQ:253590
|
$379.02 Million |
|
Hana Tour
KO:039130
|
$378.43 Million |
|
Siamgas and Petrochemicals Public Company Limited
BK:SGP-R
|
$378.08 Million |
|
Nanjing Textiles Import & Export Corp Ltd
SHG:600250
|
$378.07 Million |
|
ABG Sundal Collier Holding ASA
OL:ABG
|
$378.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanhua Bio Medicine Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 237,095,180 to 265,751,171, a change of 28,655,991 (12.1%).
- Net income of 28,828,686 contributed positively to equity growth.
- Dividend payments of 2,365,152 reduced retained earnings.
- Other comprehensive income decreased equity by 44,698,833.
- Other factors increased equity by 46,891,290.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥28.83 Million | +10.85% |
| Dividends Paid | CN¥2.37 Million | -0.89% |
| Other Comprehensive Income | CN¥-44.70 Million | -16.82% |
| Other Changes | CN¥46.89 Million | +17.64% |
| Total Change | CN¥- | 12.09% |
Book Value vs Market Value Analysis
This analysis compares Nanhua Bio Medicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.98x to 9.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1992-12-31 | CN¥0.56 | CN¥7.84 | x |
| 1993-12-31 | CN¥1.78 | CN¥7.84 | x |
| 1994-12-31 | CN¥1.95 | CN¥7.84 | x |
| 1995-12-31 | CN¥2.01 | CN¥7.84 | x |
| 1996-12-31 | CN¥1.70 | CN¥7.84 | x |
| 1997-12-31 | CN¥1.73 | CN¥7.84 | x |
| 1998-12-31 | CN¥1.09 | CN¥7.84 | x |
| 1999-12-31 | CN¥0.52 | CN¥7.84 | x |
| 2000-12-31 | CN¥1.01 | CN¥7.84 | x |
| 2001-12-31 | CN¥1.04 | CN¥7.84 | x |
| 2002-12-31 | CN¥1.25 | CN¥7.84 | x |
| 2003-12-31 | CN¥1.35 | CN¥7.84 | x |
| 2004-12-31 | CN¥1.41 | CN¥7.84 | x |
| 2005-12-31 | CN¥1.42 | CN¥7.84 | x |
| 2006-12-31 | CN¥1.42 | CN¥7.84 | x |
| 2007-12-31 | CN¥1.43 | CN¥7.84 | x |
| 2008-12-31 | CN¥0.90 | CN¥7.84 | x |
| 2009-12-31 | CN¥0.46 | CN¥7.84 | x |
| 2010-12-31 | CN¥0.48 | CN¥7.84 | x |
| 2011-12-31 | CN¥0.42 | CN¥7.84 | x |
| 2012-12-31 | CN¥-0.07 | CN¥7.84 | x |
| 2013-12-31 | CN¥0.00 | CN¥7.84 | x |
| 2014-12-31 | CN¥0.01 | CN¥7.84 | x |
| 2015-12-31 | CN¥-0.05 | CN¥7.84 | x |
| 2016-12-31 | CN¥0.02 | CN¥7.84 | x |
| 2017-12-31 | CN¥0.08 | CN¥7.84 | x |
| 2018-12-31 | CN¥-0.03 | CN¥7.84 | x |
| 2019-12-31 | CN¥0.06 | CN¥7.84 | x |
| 2020-12-31 | CN¥0.10 | CN¥7.84 | x |
| 2021-12-31 | CN¥0.05 | CN¥7.84 | x |
| 2022-12-31 | CN¥0.04 | CN¥7.84 | x |
| 2023-12-31 | CN¥0.82 | CN¥7.84 | x |
| 2024-12-31 | CN¥0.72 | CN¥7.84 | x |
| 2025-12-31 | CN¥0.81 | CN¥7.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanhua Bio Medicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.85%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.93%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 3.73x
- Recent ROE (10.85%) is below the historical average (22.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1992 | 36.11% | 35.64% | 0.39x | 2.61x | CN¥45.52 Million |
| 1993 | 23.26% | 40.26% | 0.41x | 1.41x | CN¥73.44 Million |
| 1994 | 9.30% | 40.56% | 0.17x | 1.37x | CN¥-4.25 Million |
| 1995 | -1.46% | -18.85% | 0.06x | 1.38x | CN¥-71.53 Million |
| 1996 | -18.39% | 0.00% | -0.13x | 1.45x | CN¥-149.68 Million |
| 1997 | 1.93% | 6.11% | 0.23x | 1.38x | CN¥-43.38 Million |
| 1998 | -55.76% | 0.00% | -0.08x | 1.86x | CN¥-223.65 Million |
| 1999 | -34.99% | 0.00% | -0.06x | 2.96x | CN¥-72.80 Million |
| 2000 | 8.97% | 130.99% | 0.04x | 1.90x | CN¥-3.24 Million |
| 2001 | 1.58% | 2.91% | 0.29x | 1.86x | CN¥-27.14 Million |
| 2002 | 7.50% | 11.64% | 0.40x | 1.60x | CN¥-9.69 Million |
| 2003 | 7.60% | 12.45% | 0.43x | 1.42x | CN¥-10.06 Million |
| 2004 | 6.78% | 10.89% | 0.45x | 1.37x | CN¥-14.16 Million |
| 2005 | 0.47% | 0.92% | 0.34x | 1.47x | CN¥-42.11 Million |
| 2006 | 0.50% | 0.98% | 0.36x | 1.44x | CN¥-42.15 Million |
| 2007 | 0.82% | 1.15% | 0.47x | 1.52x | CN¥-41.23 Million |
| 2008 | -61.14% | -86.13% | 0.37x | 1.93x | CN¥-197.88 Million |
| 2009 | -94.43% | -75.52% | 0.43x | 2.89x | CN¥-148.92 Million |
| 2010 | 4.14% | 4.25% | 0.53x | 1.84x | CN¥-9.16 Million |
| 2011 | -23.68% | -32.90% | 0.33x | 2.19x | CN¥-42.53 Million |
| 2012 | 0.00% | -194.27% | 1.01x | 0.00x | CN¥-146.93 Million |
| 2013 | 1307.97% | 52.52% | 0.21x | 119.31x | CN¥13.70 Million |
| 2014 | -555.30% | -142.34% | 0.17x | 22.64x | CN¥-26.62 Million |
| 2015 | 0.00% | -158.65% | 0.11x | 0.00x | CN¥-19.57 Million |
| 2016 | 412.63% | 32.35% | 0.22x | 57.12x | CN¥21.23 Million |
| 2017 | -150.63% | -55.08% | 0.17x | 16.43x | CN¥-39.58 Million |
| 2018 | 0.00% | -36.89% | 0.28x | 0.00x | CN¥-34.16 Million |
| 2019 | 102.13% | 14.02% | 0.50x | 14.57x | CN¥16.96 Million |
| 2020 | 30.69% | 4.64% | 0.32x | 20.93x | CN¥5.50 Million |
| 2021 | -114.94% | -12.21% | 0.24x | 39.62x | CN¥-20.79 Million |
| 2022 | -90.46% | -6.22% | 0.36x | 40.16x | CN¥-13.83 Million |
| 2023 | -10.96% | -20.60% | 0.18x | 3.00x | CN¥-53.87 Million |
| 2024 | -8.37% | -14.76% | 0.22x | 2.57x | CN¥-43.56 Million |
| 2025 | 10.85% | 6.93% | 0.42x | 3.73x | CN¥2.25 Million |
Industry Comparison
This section compares Nanhua Bio Medicine Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,777,495,990
- Average return on equity (ROE) among peers: 5.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanhua Bio Medicine Co Ltd (000504) | CN¥369.07 Million | 36.11% | 1.75x | $378.62 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $1.40 Billion | -0.26% | 0.06x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.50 Billion |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $512.78 Million | -14.68% | 0.29x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $13.85 Billion | 7.86% | 0.18x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.45 Billion | 1.65% | 0.22x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.05 Billion | 15.59% | 0.13x | $1.64 Billion |
About Nanhua Bio Medicine Co Ltd
Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. It operates in two segments, Biomedicine, and Energy Saving and Environmental Protection. The Biomedicine segment engages in the provision of stem cell, immune cell storage and technical services, and medical device trade. The Energy Saving and Environmental Protection segment is involved in the external energy management … Read more